Research And Development Expense, Offset From Cost Reimbursement

No definition available.

Name:	dnli_ResearchAndDevelopmentExpenseOffsetFromCostReimbursement
Namespace Prefix:	dnli_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 310
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477802/946-310-45-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(5)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479196/954-310-45-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:	us-gaap_AccountsReceivableNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=dnli_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementPTVPGRNMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementATVTREM2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnli_CollaborativeArrangementPTVPGRNAndATVTREM2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dnli_BiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnli_LRRK2ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnli_BiogenCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - Schedule of Cost Sharing Payments and Reimbursements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net cost sharing payments (reimbursements)	$ 732,000	$ 2,171,000	$ 3,489,000	$ 7,969,000
Accrued expenses and other current liabilities	81,558,000		81,558,000		$ 97,846,000
Takeda Pharmaceutical Company Limited
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net cost sharing payments (reimbursements)	0	(1,929,000)	(3,130,000)	(5,011,000)
Takeda Pharmaceutical Company Limited \| Collaborative Arrangement, PTV:PGRN
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net cost sharing payments (reimbursements)	0	(1,929,000)	(3,130,000)	(4,864,000)
Takeda Pharmaceutical Company Limited \| Collaborative Arrangement, ATV:TREM2
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net cost sharing payments (reimbursements)	0	0	0	(147,000)
Takeda Pharmaceutical Company Limited \| Collaborative Arrangement, PTV:PGRN and ATV:TREM2
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable	0		0		1,600,000
Biogen \| LRRK2 Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net cost sharing payments (reimbursements)	732,000	$ 4,100,000	6,619,000	$ 12,980,000
Biogen \| Biogen Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued expenses and other current liabilities	$ 700,000		$ 700,000		$ 2,800,000